Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

N/A(4)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02726945Not ApplicableCompleted

Adipose-derived SVF for the Treatment of Knee OA

Role: lead

NCT03886402Not ApplicableWithdrawn

Adipose-derived SVF for Treatment of Erectile Dysfunction (ED)

Role: lead

NCT04440189Phase 3Active Not Recruiting

Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis

Role: lead

NCT06940765Not ApplicableWithdrawn

Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19

Role: lead

NCT05699161Phase 1Completed

Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

Role: collaborator

NCT02626780Not ApplicableCompleted

Adipose-derived SVF for Treatment of Alopecia

Role: lead

All 6 trials loaded